Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/94695
Title:
Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer.
Authors:
Thatcher, Nick; Jayson, Gordon C ( 0000-0002-8515-8944 ) ; Bradley, B; Ranson, Malcolm R; Anderson, Heather
Abstract:
Recent studies have indicated that chemotherapy not only provides some survival benefit, but also reduces tumor-related symptoms and improves the performance status of patients receiving chemotherapy. Data from single-agent gemcitabine studies demonstrate improvements in a range of tumor symptoms, including cough, hemoptysis, pain, dyspnea, and anorexia, as well as increases in performance status. Indeed, more patients benefit from gemcitabine chemotherapy than suggested by the objective response rate. Surveys also have shown that patients are much more likely to accept chemotherapy for what is perceived by health care professionals as potentially small benefits. Gemcitabine has a role in the palliative treatment of patients with advanced non-small cell lung cancer.
Affiliation:
CRC Department of Medical Oncology, Christie and Wythenshawe Hospitals, Manchester, England.
Citation:
Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer. 1997, 24 (3 Suppl 8):S8-6-S8-12 Semin. Oncol.
Journal:
Seminars in Oncology
Issue Date:
Jun-1997
URI:
http://hdl.handle.net/10541/94695
PubMed ID:
9207309
Type:
Article
Language:
en
ISSN:
0093-7754
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorThatcher, Nicken
dc.contributor.authorJayson, Gordon Cen
dc.contributor.authorBradley, Ben
dc.contributor.authorRanson, Malcolm Ren
dc.contributor.authorAnderson, Heatheren
dc.date.accessioned2010-03-23T13:07:32Z-
dc.date.available2010-03-23T13:07:32Z-
dc.date.issued1997-06-
dc.identifier.citationGemcitabine: symptomatic benefit in advanced non-small cell lung cancer. 1997, 24 (3 Suppl 8):S8-6-S8-12 Semin. Oncol.en
dc.identifier.issn0093-7754-
dc.identifier.pmid9207309-
dc.identifier.urihttp://hdl.handle.net/10541/94695-
dc.description.abstractRecent studies have indicated that chemotherapy not only provides some survival benefit, but also reduces tumor-related symptoms and improves the performance status of patients receiving chemotherapy. Data from single-agent gemcitabine studies demonstrate improvements in a range of tumor symptoms, including cough, hemoptysis, pain, dyspnea, and anorexia, as well as increases in performance status. Indeed, more patients benefit from gemcitabine chemotherapy than suggested by the objective response rate. Surveys also have shown that patients are much more likely to accept chemotherapy for what is perceived by health care professionals as potentially small benefits. Gemcitabine has a role in the palliative treatment of patients with advanced non-small cell lung cancer.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAntimetabolites, Antineoplastic-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshDeoxycytidine-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshRibonucleotide Reductases-
dc.subject.meshTreatment Outcome-
dc.titleGemcitabine: symptomatic benefit in advanced non-small cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie and Wythenshawe Hospitals, Manchester, England.en
dc.identifier.journalSeminars in Oncologyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.